PIPE

Pipe Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapies for patients with neurodegenerative and neuro-ophthalmological diseases. The company leverages its proprietary discovery platform to identify highly selective modulators of targets that promote remyelination and provide neuroprotection. Pipe's lead candidate, PIPE-307, is a selective M1 receptor antagonist currently in Phase 2 clinical trials for multiple sclerosis, developed in collaboration with AbbVie. Additionally, the company is advancing PIPE-791, a selective LPA1 receptor antagonist, for the treatment of idiopathic pulmonary fibrosis and neuroinflammatory conditions. Pipe Therapeutics is backed by a syndicate of leading life science investors and is headquartered in San Diego, California.